Co-Authors
This is a "connection" page, showing publications co-authored by Mark Ratain and Austin Wesevich.
Connection Strength
5.641
-
Formulation-Based Cost Savings with Cabozantinib Capsules. JAMA Oncol. 2025 Apr 03.
Score: 0.969
-
Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
Score: 0.925
-
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States. Ann Intern Med. 2024 01; 177(1):85-86.
Score: 0.883
-
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 11 01; 9(11):1489-1490.
Score: 0.878
-
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest? Nat Biotechnol. 2023 Nov; 41(11):1517-1519.
Score: 0.878
-
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023 10; 129(9):1389-1396.
Score: 0.863
-
Triaging acute chest syndrome clinical decision-making using bedside SaO2/FiO2 ratio. Blood Adv. 2025 Jun 24; 9(12):2970-2979.
Score: 0.246